Nykode Therapeutics AS (OB: NYKD)
Health Care · Biotechnology · NO
Nkr4.64
+2.88% today · +150.6% 1Y
Nykode Therapeutics AS (OB: NYKD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $158.32M and employs 57 people.
Over the last twelve months the share price has gained 150.6%, trading between 1.44 and 5.17.
Tweenvest scores Nykode Therapeutics AS across four factors: quality 36/100, value 45/100, dividend 90/100. Its strongest factor is dividend.
NYKD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $158.32M
- Revenue (TTM)
- $556.00K
- P/E
- —
- EPS
- -0.05
- Dividend yield
- 22.17%
- Beta (5Y)
- 0.81
- 52-week high
- Nkr5.17
- 52-week low
- Nkr1.44
- Avg volume (3M)
- —
- Shares outstanding
- 326.55M
- Employees
- 57
- Next earnings
- —
About Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
- ISIN
- NO0010714785
- Founded
- 2006
- Listed since
- Oct 7, 2020
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.